<DOC>
	<DOCNO>NCT02776735</DOCNO>
	<brief_summary>Primary Objective : To describe pharmacokinetic ( PK ) profile sarilumab patient pcJIA order identify dose regimen continue development population . Secondary Objective : To describe : - The pharmacodynamic ( PD ) profile , efficacy safety sarilumab patient pcJIA . - The long-term safety sarilumab patient pcJIA .</brief_summary>
	<brief_title>An Open-label , Ascending , Repeated Dose-finding Study Sarilumab Children Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis ( pcJIA )</brief_title>
	<detailed_description>The total study duration per patient 114 week consist 4-week screening , 12-week core treatment period , 92-week extension phase , 6-week post-treatment follow-up .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Inclusion criterion : Male female patient age ≥2 ≤17 year time screen visit . Diagnosis rheumatoid factornegative rheumatoid factor positive polyarticular Juvenile Idiopathic Arthritis ( JIA ) subtype oligoarticular extend JIA subtype accord International League Associations Rheumatology ( ILAR ) 2001 Juvenile Idiopathic Arthritis Classification Criteria least 5 active joint per American College Rheumatology ( ACR ) definition `` active arthritis '' screen . Patient inadequate response current treatment consider candidate biologic diseasemodifying antirheumatic drug ( DMARD ) per Investigator 's judgment . Exclusion criterion : Body weight &lt; 10 kg &gt; 60 kg . If nonsteroidal antiinflammatory drug ( NSAIDs , include cyclooxygenase2 inhibitor [ COX2 ] ) take , dose stable less 2 week prior baseline visit and/or dose prescribed outside approved label . If nonbiologic DMARD take , dose stable less 6 week prior baseline visit dose exceed recommend dose per local labeling . If oral glucocorticoid take , dose exceed equivalent prednisone dose 0.5 mg/kg/day ( 30 mg/day ) within 2 week prior baseline . Prior treatment antiinterleukin 6 ( IL6 ) IL6 receptor ( IL6R ) antagonist therapy , include limited tocilizumab sarilumab . Treatment biologic DMARD within 5 halflives prior first dose sarilumab Treatment Janus kinase inhibitor within 4 week prior first dose sarilumab Treatment investigational biologic nonbiologic product within 8 week 5 halflives prior baseline , whichever longer . Active tuberculosis patient latent tuberculosis patient without adequate treatment . Exclusion criterion relate past current infection tuberculosis . Any live , attenuated vaccine within 4 week prior baseline , varicellazoster , oral polio , rubella vaccine . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>